nodes	percent_of_prediction	percent_of_DWPC	metapath
Milnacipran—Levomilnacipran—CYP2C19—prostate cancer	0.00329	0.421	CrCbGaD
Milnacipran—Levomilnacipran—CYP3A4—prostate cancer	0.00209	0.268	CrCbGaD
Milnacipran—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC22A1—prostate cancer	0.00162	0.0395	CbGpPWpGaD
Milnacipran—SLC6A4—Serotonin Transporter Activity—ITGB3—prostate cancer	0.0015	0.0364	CbGpPWpGaD
Milnacipran—Pethidine—CYP2C19—prostate cancer	0.00148	0.19	CrCbGaD
Milnacipran—SLC6A2—Amine compound SLC transporters—SLC22A1—prostate cancer	0.00113	0.0274	CbGpPWpGaD
Milnacipran—SLC6A4—Monoamine Transport—ACHE—prostate cancer	0.00105	0.0256	CbGpPWpGaD
Milnacipran—SLC6A4—Synaptic Vesicle Pathway—SLC22A3—prostate cancer	0.00105	0.0255	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—NKX3-1—prostate cancer	0.00103	0.0252	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—ZFHX3—prostate cancer	0.000993	0.0242	CbGpPWpGaD
Milnacipran—Pethidine—CYP3A4—prostate cancer	0.000943	0.121	CrCbGaD
Milnacipran—SLC6A2—Monoamine Transport—ACHE—prostate cancer	0.000906	0.022	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—CBR1—prostate cancer	0.000889	0.0216	CbGpPWpGaD
Milnacipran—SLC6A4—Monoamine Transport—TH—prostate cancer	0.000863	0.021	CbGpPWpGaD
Milnacipran—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A1—prostate cancer	0.000838	0.0204	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—GSTM3—prostate cancer	0.000777	0.0189	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—CBR1—prostate cancer	0.000765	0.0186	CbGpPWpGaD
Milnacipran—SLC6A2—Monoamine Transport—TH—prostate cancer	0.000742	0.0181	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—SLC39A1—prostate cancer	0.000703	0.0171	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—ASCL1—prostate cancer	0.000699	0.017	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—GSTM3—prostate cancer	0.000668	0.0162	CbGpPWpGaD
Milnacipran—SLC6A4—Monoamine Transport—ITGB3—prostate cancer	0.000636	0.0155	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—SLC39A1—prostate cancer	0.000604	0.0147	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—NAGLU—prostate cancer	0.000602	0.0146	CbGpPWpGaD
Milnacipran—SLC6A2—Monoamine Transport—ITGB3—prostate cancer	0.000547	0.0133	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—ID3—prostate cancer	0.000544	0.0132	CbGpPWpGaD
Milnacipran—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A3—prostate cancer	0.00054	0.0131	CbGpPWpGaD
Milnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.000482	0.0117	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—GSTA3—prostate cancer	0.000475	0.0115	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—HSP90B1—prostate cancer	0.00045	0.0109	CbGpPWpGaD
Milnacipran—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A1—prostate cancer	0.00044	0.0107	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—GSTA4—prostate cancer	0.000434	0.0106	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—GSTA2—prostate cancer	0.000423	0.0103	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—GSTA1—prostate cancer	0.000408	0.00993	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—GSTA3—prostate cancer	0.000408	0.00993	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—HSP90AB1—prostate cancer	0.000395	0.00961	CbGpPWpGaD
Milnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000381	0.00926	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—GSTA4—prostate cancer	0.000373	0.00908	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—GSTA2—prostate cancer	0.000364	0.00885	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—NFE2L2—prostate cancer	0.00036	0.00875	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—GSTA1—prostate cancer	0.000351	0.00854	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—TGFA—prostate cancer	0.000343	0.00835	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—GPX3—prostate cancer	0.000343	0.00835	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—HSP90AB1—prostate cancer	0.00034	0.00826	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—HNF1B—prostate cancer	0.000336	0.00818	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—NFE2L2—prostate cancer	0.000309	0.00752	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—CYP2A6—prostate cancer	0.000309	0.00752	CbGpPWpGaD
Milnacipran—Infection—Docetaxel—prostate cancer	0.000304	0.00032	CcSEcCtD
Milnacipran—Weight decreased—Doxorubicin—prostate cancer	0.000304	0.00032	CcSEcCtD
Milnacipran—Diarrhoea—Mitoxantrone—prostate cancer	0.000303	0.000318	CcSEcCtD
Milnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000303	0.00736	CbGpPWpGaD
Milnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000303	0.00736	CbGpPWpGaD
Milnacipran—Dry mouth—Capecitabine—prostate cancer	0.000302	0.000318	CcSEcCtD
Milnacipran—Vomiting—Estradiol—prostate cancer	0.000302	0.000318	CcSEcCtD
Milnacipran—Gastrointestinal pain—Etoposide—prostate cancer	0.000301	0.000317	CcSEcCtD
Milnacipran—Shock—Docetaxel—prostate cancer	0.000301	0.000317	CcSEcCtD
Milnacipran—Nervous system disorder—Docetaxel—prostate cancer	0.0003	0.000316	CcSEcCtD
Milnacipran—SLC6A4—Circadian rythm related genes—PRKDC—prostate cancer	0.0003	0.00729	CbGpPWpGaD
Milnacipran—Thrombocytopenia—Docetaxel—prostate cancer	0.0003	0.000315	CcSEcCtD
Milnacipran—Rash—Estradiol—prostate cancer	0.0003	0.000315	CcSEcCtD
Milnacipran—Dermatitis—Estradiol—prostate cancer	0.000299	0.000315	CcSEcCtD
Milnacipran—Tachycardia—Docetaxel—prostate cancer	0.000299	0.000314	CcSEcCtD
Milnacipran—Headache—Estradiol—prostate cancer	0.000298	0.000313	CcSEcCtD
Milnacipran—Skin disorder—Docetaxel—prostate cancer	0.000297	0.000313	CcSEcCtD
Milnacipran—Agitation—Prednisone—prostate cancer	0.000297	0.000312	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	0.000297	0.000312	CcSEcCtD
Milnacipran—SLC6A2—NRF2 pathway—GPX3—prostate cancer	0.000295	0.00718	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—TGFA—prostate cancer	0.000295	0.00718	CbGpPWpGaD
Milnacipran—Infection—Capecitabine—prostate cancer	0.000294	0.00031	CcSEcCtD
Milnacipran—Urticaria—Etoposide—prostate cancer	0.000293	0.000308	CcSEcCtD
Milnacipran—Anorexia—Docetaxel—prostate cancer	0.000292	0.000307	CcSEcCtD
Milnacipran—Shock—Capecitabine—prostate cancer	0.000292	0.000307	CcSEcCtD
Milnacipran—Body temperature increased—Etoposide—prostate cancer	0.000291	0.000306	CcSEcCtD
Milnacipran—Abdominal pain—Etoposide—prostate cancer	0.000291	0.000306	CcSEcCtD
Milnacipran—Urinary tract infection—Doxorubicin—prostate cancer	0.000291	0.000306	CcSEcCtD
Milnacipran—Nervous system disorder—Capecitabine—prostate cancer	0.000291	0.000306	CcSEcCtD
Milnacipran—Hepatitis—Epirubicin—prostate cancer	0.000291	0.000305	CcSEcCtD
Milnacipran—Thrombocytopenia—Capecitabine—prostate cancer	0.00029	0.000305	CcSEcCtD
Milnacipran—Syncope—Prednisone—prostate cancer	0.00029	0.000305	CcSEcCtD
Milnacipran—Tachycardia—Capecitabine—prostate cancer	0.000289	0.000304	CcSEcCtD
Milnacipran—Hypoaesthesia—Epirubicin—prostate cancer	0.000289	0.000304	CcSEcCtD
Milnacipran—Skin disorder—Capecitabine—prostate cancer	0.000288	0.000303	CcSEcCtD
Milnacipran—Urinary tract disorder—Epirubicin—prostate cancer	0.000287	0.000302	CcSEcCtD
Milnacipran—Hyperhidrosis—Capecitabine—prostate cancer	0.000286	0.000301	CcSEcCtD
Milnacipran—Oedema peripheral—Epirubicin—prostate cancer	0.000286	0.000301	CcSEcCtD
Milnacipran—Hypotension—Docetaxel—prostate cancer	0.000286	0.000301	CcSEcCtD
Milnacipran—SLC6A4—Circadian rythm related genes—AHR—prostate cancer	0.000286	0.00695	CbGpPWpGaD
Milnacipran—Haematuria—Doxorubicin—prostate cancer	0.000286	0.0003	CcSEcCtD
Milnacipran—Connective tissue disorder—Epirubicin—prostate cancer	0.000286	0.0003	CcSEcCtD
Milnacipran—Urethral disorder—Epirubicin—prostate cancer	0.000285	0.000299	CcSEcCtD
Milnacipran—Loss of consciousness—Prednisone—prostate cancer	0.000284	0.000299	CcSEcCtD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—PRKACB—prostate cancer	0.000284	0.0069	CbGpPWpGaD
Milnacipran—Hepatobiliary disease—Doxorubicin—prostate cancer	0.000283	0.000298	CcSEcCtD
Milnacipran—Anorexia—Capecitabine—prostate cancer	0.000282	0.000297	CcSEcCtD
Milnacipran—Nausea—Estradiol—prostate cancer	0.000282	0.000297	CcSEcCtD
Milnacipran—Vomiting—Mitoxantrone—prostate cancer	0.000281	0.000296	CcSEcCtD
Milnacipran—Convulsion—Prednisone—prostate cancer	0.00028	0.000295	CcSEcCtD
Milnacipran—Hypertension—Prednisone—prostate cancer	0.000279	0.000294	CcSEcCtD
Milnacipran—Rash—Mitoxantrone—prostate cancer	0.000279	0.000294	CcSEcCtD
Milnacipran—Dermatitis—Mitoxantrone—prostate cancer	0.000279	0.000293	CcSEcCtD
Milnacipran—Headache—Mitoxantrone—prostate cancer	0.000277	0.000292	CcSEcCtD
Milnacipran—Hypotension—Capecitabine—prostate cancer	0.000277	0.000291	CcSEcCtD
Milnacipran—Insomnia—Docetaxel—prostate cancer	0.000277	0.000291	CcSEcCtD
Milnacipran—Paraesthesia—Docetaxel—prostate cancer	0.000275	0.000289	CcSEcCtD
Milnacipran—Erythema multiforme—Epirubicin—prostate cancer	0.000275	0.000289	CcSEcCtD
Milnacipran—Anxiety—Prednisone—prostate cancer	0.000274	0.000288	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000273	0.000287	CcSEcCtD
Milnacipran—Dyspnoea—Docetaxel—prostate cancer	0.000273	0.000287	CcSEcCtD
Milnacipran—Somnolence—Docetaxel—prostate cancer	0.000272	0.000286	CcSEcCtD
Milnacipran—Eye disorder—Epirubicin—prostate cancer	0.000272	0.000285	CcSEcCtD
Milnacipran—Hypersensitivity—Etoposide—prostate cancer	0.000271	0.000285	CcSEcCtD
Milnacipran—Cardiac disorder—Epirubicin—prostate cancer	0.00027	0.000284	CcSEcCtD
Milnacipran—Flushing—Epirubicin—prostate cancer	0.00027	0.000284	CcSEcCtD
Milnacipran—Dyspepsia—Docetaxel—prostate cancer	0.000269	0.000283	CcSEcCtD
Milnacipran—SLC6A4—NRF2 pathway—SLC5A5—prostate cancer	0.000269	0.00655	CbGpPWpGaD
Milnacipran—Hepatitis—Doxorubicin—prostate cancer	0.000269	0.000283	CcSEcCtD
Milnacipran—Insomnia—Capecitabine—prostate cancer	0.000268	0.000282	CcSEcCtD
Milnacipran—Hypoaesthesia—Doxorubicin—prostate cancer	0.000267	0.000281	CcSEcCtD
Milnacipran—Paraesthesia—Capecitabine—prostate cancer	0.000266	0.00028	CcSEcCtD
Milnacipran—Decreased appetite—Docetaxel—prostate cancer	0.000266	0.00028	CcSEcCtD
Milnacipran—SLC6A2—NRF2 pathway—CYP2A6—prostate cancer	0.000266	0.00647	CbGpPWpGaD
Milnacipran—Urinary tract disorder—Doxorubicin—prostate cancer	0.000265	0.000279	CcSEcCtD
Milnacipran—Oedema peripheral—Doxorubicin—prostate cancer	0.000265	0.000278	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000264	0.000278	CcSEcCtD
Milnacipran—Asthenia—Etoposide—prostate cancer	0.000264	0.000278	CcSEcCtD
Milnacipran—Connective tissue disorder—Doxorubicin—prostate cancer	0.000264	0.000278	CcSEcCtD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—IL1RN—prostate cancer	0.000264	0.00642	CbGpPWpGaD
Milnacipran—Dyspnoea—Capecitabine—prostate cancer	0.000264	0.000278	CcSEcCtD
Milnacipran—Fatigue—Docetaxel—prostate cancer	0.000264	0.000277	CcSEcCtD
Milnacipran—Angiopathy—Epirubicin—prostate cancer	0.000264	0.000277	CcSEcCtD
Milnacipran—Urethral disorder—Doxorubicin—prostate cancer	0.000264	0.000277	CcSEcCtD
Milnacipran—Nausea—Mitoxantrone—prostate cancer	0.000263	0.000276	CcSEcCtD
Milnacipran—Infection—Prednisone—prostate cancer	0.000262	0.000276	CcSEcCtD
Milnacipran—Mediastinal disorder—Epirubicin—prostate cancer	0.000262	0.000275	CcSEcCtD
Milnacipran—Constipation—Docetaxel—prostate cancer	0.000262	0.000275	CcSEcCtD
Milnacipran—Dyspepsia—Capecitabine—prostate cancer	0.000261	0.000274	CcSEcCtD
Milnacipran—Chills—Epirubicin—prostate cancer	0.000261	0.000274	CcSEcCtD
Milnacipran—Pruritus—Etoposide—prostate cancer	0.000261	0.000274	CcSEcCtD
Milnacipran—SLC6A4—NRF2 pathway—NQO1—prostate cancer	0.00026	0.00633	CbGpPWpGaD
Milnacipran—Shock—Prednisone—prostate cancer	0.00026	0.000273	CcSEcCtD
Milnacipran—Nervous system disorder—Prednisone—prostate cancer	0.000259	0.000272	CcSEcCtD
Milnacipran—SLC6A4—NRF2 pathway—HSPA1A—prostate cancer	0.000258	0.00628	CbGpPWpGaD
Milnacipran—Tachycardia—Prednisone—prostate cancer	0.000258	0.000271	CcSEcCtD
Milnacipran—Decreased appetite—Capecitabine—prostate cancer	0.000258	0.000271	CcSEcCtD
Milnacipran—Skin disorder—Prednisone—prostate cancer	0.000256	0.00027	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000256	0.000269	CcSEcCtD
Milnacipran—Fatigue—Capecitabine—prostate cancer	0.000255	0.000269	CcSEcCtD
Milnacipran—Hyperhidrosis—Prednisone—prostate cancer	0.000255	0.000268	CcSEcCtD
Milnacipran—Mental disorder—Epirubicin—prostate cancer	0.000255	0.000268	CcSEcCtD
Milnacipran—Erythema multiforme—Doxorubicin—prostate cancer	0.000254	0.000267	CcSEcCtD
Milnacipran—Constipation—Capecitabine—prostate cancer	0.000253	0.000266	CcSEcCtD
Milnacipran—Malnutrition—Epirubicin—prostate cancer	0.000253	0.000266	CcSEcCtD
Milnacipran—Diarrhoea—Etoposide—prostate cancer	0.000252	0.000265	CcSEcCtD
Milnacipran—Anorexia—Prednisone—prostate cancer	0.000252	0.000265	CcSEcCtD
Milnacipran—Eye disorder—Doxorubicin—prostate cancer	0.000251	0.000264	CcSEcCtD
Milnacipran—Gastrointestinal pain—Docetaxel—prostate cancer	0.00025	0.000263	CcSEcCtD
Milnacipran—Flushing—Doxorubicin—prostate cancer	0.00025	0.000262	CcSEcCtD
Milnacipran—Cardiac disorder—Doxorubicin—prostate cancer	0.00025	0.000262	CcSEcCtD
Milnacipran—Flatulence—Epirubicin—prostate cancer	0.000249	0.000262	CcSEcCtD
Milnacipran—Tension—Epirubicin—prostate cancer	0.000248	0.000261	CcSEcCtD
Milnacipran—Dysgeusia—Epirubicin—prostate cancer	0.000248	0.00026	CcSEcCtD
Milnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.000245	0.00597	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—ESR2—prostate cancer	0.000245	0.00595	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000245	0.00595	CbGpPWpGaD
Milnacipran—Angiopathy—Doxorubicin—prostate cancer	0.000244	0.000256	CcSEcCtD
Milnacipran—Dizziness—Etoposide—prostate cancer	0.000244	0.000256	CcSEcCtD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—TH—prostate cancer	0.000243	0.00591	CbGpPWpGaD
Milnacipran—Gastrointestinal pain—Capecitabine—prostate cancer	0.000242	0.000255	CcSEcCtD
Milnacipran—Mediastinal disorder—Doxorubicin—prostate cancer	0.000242	0.000255	CcSEcCtD
Milnacipran—Body temperature increased—Docetaxel—prostate cancer	0.000242	0.000254	CcSEcCtD
Milnacipran—Abdominal pain—Docetaxel—prostate cancer	0.000242	0.000254	CcSEcCtD
Milnacipran—SLC6A4—NRF2 pathway—EGR1—prostate cancer	0.000242	0.00587	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—GGT1—prostate cancer	0.000242	0.00587	CbGpPWpGaD
Milnacipran—Chills—Doxorubicin—prostate cancer	0.000241	0.000254	CcSEcCtD
Milnacipran—Insomnia—Prednisone—prostate cancer	0.000239	0.000251	CcSEcCtD
Milnacipran—Vision blurred—Epirubicin—prostate cancer	0.000238	0.000251	CcSEcCtD
Milnacipran—Paraesthesia—Prednisone—prostate cancer	0.000237	0.000249	CcSEcCtD
Milnacipran—Mental disorder—Doxorubicin—prostate cancer	0.000236	0.000248	CcSEcCtD
Milnacipran—Urticaria—Capecitabine—prostate cancer	0.000235	0.000247	CcSEcCtD
Milnacipran—Body temperature increased—Capecitabine—prostate cancer	0.000234	0.000246	CcSEcCtD
Milnacipran—Abdominal pain—Capecitabine—prostate cancer	0.000234	0.000246	CcSEcCtD
Milnacipran—Vomiting—Etoposide—prostate cancer	0.000234	0.000246	CcSEcCtD
Milnacipran—Malnutrition—Doxorubicin—prostate cancer	0.000234	0.000246	CcSEcCtD
Milnacipran—Agitation—Epirubicin—prostate cancer	0.000232	0.000244	CcSEcCtD
Milnacipran—Dyspepsia—Prednisone—prostate cancer	0.000232	0.000244	CcSEcCtD
Milnacipran—Rash—Etoposide—prostate cancer	0.000232	0.000244	CcSEcCtD
Milnacipran—Dermatitis—Etoposide—prostate cancer	0.000232	0.000244	CcSEcCtD
Milnacipran—SLC6A2—NRF2 pathway—SLC5A5—prostate cancer	0.000232	0.00563	CbGpPWpGaD
Milnacipran—Headache—Etoposide—prostate cancer	0.000231	0.000243	CcSEcCtD
Milnacipran—Flatulence—Doxorubicin—prostate cancer	0.000231	0.000242	CcSEcCtD
Milnacipran—Tension—Doxorubicin—prostate cancer	0.00023	0.000241	CcSEcCtD
Milnacipran—Decreased appetite—Prednisone—prostate cancer	0.000229	0.000241	CcSEcCtD
Milnacipran—Dysgeusia—Doxorubicin—prostate cancer	0.000229	0.000241	CcSEcCtD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—EGR1—prostate cancer	0.000229	0.00557	CbGpPWpGaD
Milnacipran—Fatigue—Prednisone—prostate cancer	0.000228	0.000239	CcSEcCtD
Milnacipran—SLC6A4—Circadian rythm related genes—TOP2A—prostate cancer	0.000227	0.00552	CbGpPWpGaD
Milnacipran—Syncope—Epirubicin—prostate cancer	0.000227	0.000238	CcSEcCtD
Milnacipran—Leukopenia—Epirubicin—prostate cancer	0.000226	0.000238	CcSEcCtD
Milnacipran—SLC6A4—NRF2 pathway—RXRA—prostate cancer	0.000226	0.0055	CbGpPWpGaD
Milnacipran—Constipation—Prednisone—prostate cancer	0.000226	0.000237	CcSEcCtD
Milnacipran—Hypersensitivity—Docetaxel—prostate cancer	0.000225	0.000237	CcSEcCtD
Milnacipran—SLC6A2—NRF2 pathway—NQO1—prostate cancer	0.000224	0.00544	CbGpPWpGaD
Milnacipran—Palpitations—Epirubicin—prostate cancer	0.000224	0.000235	CcSEcCtD
Milnacipran—Loss of consciousness—Epirubicin—prostate cancer	0.000222	0.000234	CcSEcCtD
Milnacipran—SLC6A2—NRF2 pathway—HSPA1A—prostate cancer	0.000222	0.0054	CbGpPWpGaD
Milnacipran—Vision blurred—Doxorubicin—prostate cancer	0.000221	0.000232	CcSEcCtD
Milnacipran—Asthenia—Docetaxel—prostate cancer	0.00022	0.000231	CcSEcCtD
Milnacipran—Convulsion—Epirubicin—prostate cancer	0.000219	0.00023	CcSEcCtD
Milnacipran—Nausea—Etoposide—prostate cancer	0.000219	0.00023	CcSEcCtD
Milnacipran—SLC6A4—Circadian rythm related genes—NCOA2—prostate cancer	0.000219	0.00532	CbGpPWpGaD
Milnacipran—Hypertension—Epirubicin—prostate cancer	0.000218	0.00023	CcSEcCtD
Milnacipran—Hypersensitivity—Capecitabine—prostate cancer	0.000218	0.00023	CcSEcCtD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—GJA1—prostate cancer	0.000218	0.0053	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—GSTP1—prostate cancer	0.000217	0.00528	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—TGFBR2—prostate cancer	0.000217	0.00528	CbGpPWpGaD
Milnacipran—Pruritus—Docetaxel—prostate cancer	0.000217	0.000228	CcSEcCtD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—AR—prostate cancer	0.000216	0.00526	CbGpPWpGaD
Milnacipran—Gastrointestinal pain—Prednisone—prostate cancer	0.000216	0.000227	CcSEcCtD
Milnacipran—SLC6A4—Circadian rythm related genes—EZH2—prostate cancer	0.000216	0.00524	CbGpPWpGaD
Milnacipran—Chest pain—Epirubicin—prostate cancer	0.000215	0.000226	CcSEcCtD
Milnacipran—Agitation—Doxorubicin—prostate cancer	0.000215	0.000226	CcSEcCtD
Milnacipran—Anxiety—Epirubicin—prostate cancer	0.000215	0.000226	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000214	0.000225	CcSEcCtD
Milnacipran—Asthenia—Capecitabine—prostate cancer	0.000213	0.000224	CcSEcCtD
Milnacipran—Dry mouth—Epirubicin—prostate cancer	0.000211	0.000221	CcSEcCtD
Milnacipran—Syncope—Doxorubicin—prostate cancer	0.00021	0.000221	CcSEcCtD
Milnacipran—Urticaria—Prednisone—prostate cancer	0.00021	0.00022	CcSEcCtD
Milnacipran—Pruritus—Capecitabine—prostate cancer	0.00021	0.00022	CcSEcCtD
Milnacipran—Leukopenia—Doxorubicin—prostate cancer	0.000209	0.00022	CcSEcCtD
Milnacipran—Diarrhoea—Docetaxel—prostate cancer	0.000209	0.00022	CcSEcCtD
Milnacipran—Abdominal pain—Prednisone—prostate cancer	0.000209	0.000219	CcSEcCtD
Milnacipran—Body temperature increased—Prednisone—prostate cancer	0.000209	0.000219	CcSEcCtD
Milnacipran—SLC6A2—NRF2 pathway—EGR1—prostate cancer	0.000208	0.00505	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—GGT1—prostate cancer	0.000208	0.00505	CbGpPWpGaD
Milnacipran—Palpitations—Doxorubicin—prostate cancer	0.000207	0.000217	CcSEcCtD
Milnacipran—Loss of consciousness—Doxorubicin—prostate cancer	0.000206	0.000216	CcSEcCtD
Milnacipran—Infection—Epirubicin—prostate cancer	0.000205	0.000216	CcSEcCtD
Milnacipran—Shock—Epirubicin—prostate cancer	0.000203	0.000214	CcSEcCtD
Milnacipran—Convulsion—Doxorubicin—prostate cancer	0.000203	0.000213	CcSEcCtD
Milnacipran—Diarrhoea—Capecitabine—prostate cancer	0.000203	0.000213	CcSEcCtD
Milnacipran—Nervous system disorder—Epirubicin—prostate cancer	0.000202	0.000213	CcSEcCtD
Milnacipran—Dizziness—Docetaxel—prostate cancer	0.000202	0.000213	CcSEcCtD
Milnacipran—Thrombocytopenia—Epirubicin—prostate cancer	0.000202	0.000213	CcSEcCtD
Milnacipran—Hypertension—Doxorubicin—prostate cancer	0.000202	0.000212	CcSEcCtD
Milnacipran—Tachycardia—Epirubicin—prostate cancer	0.000201	0.000212	CcSEcCtD
Milnacipran—Skin disorder—Epirubicin—prostate cancer	0.000201	0.000211	CcSEcCtD
Milnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.0002	0.00487	CbGpPWpGaD
Milnacipran—Hyperhidrosis—Epirubicin—prostate cancer	0.0002	0.00021	CcSEcCtD
Milnacipran—SLC6A4—NRF2 pathway—GSTM1—prostate cancer	0.000199	0.00485	CbGpPWpGaD
Milnacipran—Chest pain—Doxorubicin—prostate cancer	0.000199	0.000209	CcSEcCtD
Milnacipran—Anxiety—Doxorubicin—prostate cancer	0.000199	0.000209	CcSEcCtD
Milnacipran—SLC6A4—Circadian rythm related genes—TH—prostate cancer	0.000198	0.00483	CbGpPWpGaD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000198	0.000208	CcSEcCtD
Milnacipran—Anorexia—Epirubicin—prostate cancer	0.000197	0.000207	CcSEcCtD
Milnacipran—Dizziness—Capecitabine—prostate cancer	0.000196	0.000206	CcSEcCtD
Milnacipran—Dry mouth—Doxorubicin—prostate cancer	0.000195	0.000205	CcSEcCtD
Milnacipran—Vomiting—Docetaxel—prostate cancer	0.000195	0.000205	CcSEcCtD
Milnacipran—SLC6A2—NRF2 pathway—RXRA—prostate cancer	0.000195	0.00473	CbGpPWpGaD
Milnacipran—Hypersensitivity—Prednisone—prostate cancer	0.000194	0.000204	CcSEcCtD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.000194	0.00471	CbGpPWpGaD
Milnacipran—Rash—Docetaxel—prostate cancer	0.000193	0.000203	CcSEcCtD
Milnacipran—Hypotension—Epirubicin—prostate cancer	0.000193	0.000203	CcSEcCtD
Milnacipran—Dermatitis—Docetaxel—prostate cancer	0.000193	0.000203	CcSEcCtD
Milnacipran—Headache—Docetaxel—prostate cancer	0.000192	0.000202	CcSEcCtD
Milnacipran—Infection—Doxorubicin—prostate cancer	0.00019	0.0002	CcSEcCtD
Milnacipran—Asthenia—Prednisone—prostate cancer	0.000189	0.000199	CcSEcCtD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—IL10—prostate cancer	0.000189	0.0046	CbGpPWpGaD
Milnacipran—Vomiting—Capecitabine—prostate cancer	0.000188	0.000198	CcSEcCtD
Milnacipran—Shock—Doxorubicin—prostate cancer	0.000188	0.000198	CcSEcCtD
Milnacipran—Nervous system disorder—Doxorubicin—prostate cancer	0.000187	0.000197	CcSEcCtD
Milnacipran—SLC6A4—Circadian rythm related genes—EGR1—prostate cancer	0.000187	0.00455	CbGpPWpGaD
Milnacipran—Thrombocytopenia—Doxorubicin—prostate cancer	0.000187	0.000197	CcSEcCtD
Milnacipran—Rash—Capecitabine—prostate cancer	0.000187	0.000196	CcSEcCtD
Milnacipran—Pruritus—Prednisone—prostate cancer	0.000187	0.000196	CcSEcCtD
Milnacipran—Insomnia—Epirubicin—prostate cancer	0.000187	0.000196	CcSEcCtD
Milnacipran—Dermatitis—Capecitabine—prostate cancer	0.000187	0.000196	CcSEcCtD
Milnacipran—SLC6A2—NRF2 pathway—GSTP1—prostate cancer	0.000187	0.00454	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—TGFBR2—prostate cancer	0.000187	0.00454	CbGpPWpGaD
Milnacipran—Tachycardia—Doxorubicin—prostate cancer	0.000186	0.000196	CcSEcCtD
Milnacipran—SLC6A4—Circadian rythm related genes—NGFR—prostate cancer	0.000186	0.00452	CbGpPWpGaD
Milnacipran—Headache—Capecitabine—prostate cancer	0.000186	0.000195	CcSEcCtD
Milnacipran—Skin disorder—Doxorubicin—prostate cancer	0.000186	0.000195	CcSEcCtD
Milnacipran—Paraesthesia—Epirubicin—prostate cancer	0.000185	0.000195	CcSEcCtD
Milnacipran—Hyperhidrosis—Doxorubicin—prostate cancer	0.000185	0.000194	CcSEcCtD
Milnacipran—Dyspnoea—Epirubicin—prostate cancer	0.000184	0.000194	CcSEcCtD
Milnacipran—Somnolence—Epirubicin—prostate cancer	0.000184	0.000193	CcSEcCtD
Milnacipran—Anorexia—Doxorubicin—prostate cancer	0.000182	0.000191	CcSEcCtD
Milnacipran—Nausea—Docetaxel—prostate cancer	0.000182	0.000191	CcSEcCtD
Milnacipran—Dyspepsia—Epirubicin—prostate cancer	0.000182	0.000191	CcSEcCtD
Milnacipran—Diarrhoea—Prednisone—prostate cancer	0.000181	0.00019	CcSEcCtD
Milnacipran—Decreased appetite—Epirubicin—prostate cancer	0.000179	0.000189	CcSEcCtD
Milnacipran—Hypotension—Doxorubicin—prostate cancer	0.000178	0.000188	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000178	0.000187	CcSEcCtD
Milnacipran—Fatigue—Epirubicin—prostate cancer	0.000178	0.000187	CcSEcCtD
Milnacipran—Constipation—Epirubicin—prostate cancer	0.000177	0.000186	CcSEcCtD
Milnacipran—Nausea—Capecitabine—prostate cancer	0.000176	0.000185	CcSEcCtD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—NR3C1—prostate cancer	0.000175	0.00425	CbGpPWpGaD
Milnacipran—Dizziness—Prednisone—prostate cancer	0.000175	0.000184	CcSEcCtD
Milnacipran—Insomnia—Doxorubicin—prostate cancer	0.000173	0.000182	CcSEcCtD
Milnacipran—Paraesthesia—Doxorubicin—prostate cancer	0.000172	0.00018	CcSEcCtD
Milnacipran—SLC6A2—NRF2 pathway—GSTM1—prostate cancer	0.000171	0.00417	CbGpPWpGaD
Milnacipran—Dyspnoea—Doxorubicin—prostate cancer	0.00017	0.000179	CcSEcCtD
Milnacipran—Somnolence—Doxorubicin—prostate cancer	0.00017	0.000179	CcSEcCtD
Milnacipran—Gastrointestinal pain—Epirubicin—prostate cancer	0.000169	0.000177	CcSEcCtD
Milnacipran—Dyspepsia—Doxorubicin—prostate cancer	0.000168	0.000177	CcSEcCtD
Milnacipran—Vomiting—Prednisone—prostate cancer	0.000168	0.000176	CcSEcCtD
Milnacipran—Rash—Prednisone—prostate cancer	0.000166	0.000175	CcSEcCtD
Milnacipran—Dermatitis—Prednisone—prostate cancer	0.000166	0.000175	CcSEcCtD
Milnacipran—Decreased appetite—Doxorubicin—prostate cancer	0.000166	0.000175	CcSEcCtD
Milnacipran—Headache—Prednisone—prostate cancer	0.000165	0.000174	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000165	0.000173	CcSEcCtD
Milnacipran—Fatigue—Doxorubicin—prostate cancer	0.000165	0.000173	CcSEcCtD
Milnacipran—Urticaria—Epirubicin—prostate cancer	0.000164	0.000172	CcSEcCtD
Milnacipran—Constipation—Doxorubicin—prostate cancer	0.000163	0.000172	CcSEcCtD
Milnacipran—Abdominal pain—Epirubicin—prostate cancer	0.000163	0.000172	CcSEcCtD
Milnacipran—Body temperature increased—Epirubicin—prostate cancer	0.000163	0.000172	CcSEcCtD
Milnacipran—SLC6A4—Circadian rythm related genes—SIRT1—prostate cancer	0.000161	0.00392	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—HIF1A—prostate cancer	0.000159	0.00388	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000158	0.00384	CbGpPWpGaD
Milnacipran—Nausea—Prednisone—prostate cancer	0.000157	0.000165	CcSEcCtD
Milnacipran—Gastrointestinal pain—Doxorubicin—prostate cancer	0.000156	0.000164	CcSEcCtD
Milnacipran—SLC6A4—Circadian rythm related genes—TYMS—prostate cancer	0.000156	0.0038	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000154	0.00374	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000154	0.00374	CbGpPWpGaD
Milnacipran—Hypersensitivity—Epirubicin—prostate cancer	0.000152	0.00016	CcSEcCtD
Milnacipran—Urticaria—Doxorubicin—prostate cancer	0.000152	0.00016	CcSEcCtD
Milnacipran—Body temperature increased—Doxorubicin—prostate cancer	0.000151	0.000159	CcSEcCtD
Milnacipran—Abdominal pain—Doxorubicin—prostate cancer	0.000151	0.000159	CcSEcCtD
Milnacipran—Asthenia—Epirubicin—prostate cancer	0.000148	0.000156	CcSEcCtD
Milnacipran—Pruritus—Epirubicin—prostate cancer	0.000146	0.000154	CcSEcCtD
Milnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	0.000146	0.00355	CbGpPWpGaD
Milnacipran—Diarrhoea—Epirubicin—prostate cancer	0.000141	0.000149	CcSEcCtD
Milnacipran—Hypersensitivity—Doxorubicin—prostate cancer	0.000141	0.000148	CcSEcCtD
Milnacipran—Asthenia—Doxorubicin—prostate cancer	0.000137	0.000144	CcSEcCtD
Milnacipran—Dizziness—Epirubicin—prostate cancer	0.000137	0.000144	CcSEcCtD
Milnacipran—Pruritus—Doxorubicin—prostate cancer	0.000135	0.000142	CcSEcCtD
Milnacipran—SLC6A4—Circadian rythm related genes—PPARA—prostate cancer	0.000134	0.00325	CbGpPWpGaD
Milnacipran—Vomiting—Epirubicin—prostate cancer	0.000131	0.000138	CcSEcCtD
Milnacipran—Diarrhoea—Doxorubicin—prostate cancer	0.000131	0.000137	CcSEcCtD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—CREBBP—prostate cancer	0.00013	0.00317	CbGpPWpGaD
Milnacipran—Rash—Epirubicin—prostate cancer	0.00013	0.000137	CcSEcCtD
Milnacipran—Dermatitis—Epirubicin—prostate cancer	0.00013	0.000137	CcSEcCtD
Milnacipran—Headache—Epirubicin—prostate cancer	0.000129	0.000136	CcSEcCtD
Milnacipran—SLC6A4—Circadian rythm related genes—LEP—prostate cancer	0.000127	0.00309	CbGpPWpGaD
Milnacipran—Dizziness—Doxorubicin—prostate cancer	0.000126	0.000133	CcSEcCtD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—SLC22A3—prostate cancer	0.000125	0.00303	CbGpPWpGaD
Milnacipran—Nausea—Epirubicin—prostate cancer	0.000123	0.000129	CcSEcCtD
Milnacipran—Vomiting—Doxorubicin—prostate cancer	0.000121	0.000128	CcSEcCtD
Milnacipran—Rash—Doxorubicin—prostate cancer	0.00012	0.000127	CcSEcCtD
Milnacipran—Dermatitis—Doxorubicin—prostate cancer	0.00012	0.000127	CcSEcCtD
Milnacipran—Headache—Doxorubicin—prostate cancer	0.00012	0.000126	CcSEcCtD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—ABCG5—prostate cancer	0.000115	0.0028	CbGpPWpGaD
Milnacipran—Nausea—Doxorubicin—prostate cancer	0.000113	0.000119	CcSEcCtD
Milnacipran—SLC6A4—Circadian rythm related genes—GSK3B—prostate cancer	0.00011	0.00267	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—CXCL8—prostate cancer	0.000103	0.00251	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—SLC22A1—prostate cancer	0.000102	0.00247	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—SERPINE1—prostate cancer	9.97e-05	0.00242	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—CASP3—prostate cancer	9.89e-05	0.00241	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—GNG5—prostate cancer	9.67e-05	0.00235	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—prostate cancer	9.54e-05	0.00232	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—EP300—prostate cancer	8.86e-05	0.00216	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—VEGFA—prostate cancer	8.4e-05	0.00204	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—PRKACB—prostate cancer	8.24e-05	0.002	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—TGFB1—prostate cancer	8.13e-05	0.00198	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—NCOA2—prostate cancer	7.77e-05	0.00189	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—PTEN—prostate cancer	7.59e-05	0.00185	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—SLC5A5—prostate cancer	7.42e-05	0.0018	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—EP300—prostate cancer	7.24e-05	0.00176	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—TGFB1—prostate cancer	6.99e-05	0.0017	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—NCOA1—prostate cancer	6.55e-05	0.00159	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—RXRA—prostate cancer	6.23e-05	0.00152	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—IL6—prostate cancer	5.81e-05	0.00141	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—TP53—prostate cancer	5.18e-05	0.00126	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—PPARA—prostate cancer	4.76e-05	0.00116	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—IL6—prostate cancer	4.74e-05	0.00115	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—CREBBP—prostate cancer	3.78e-05	0.000919	CbGpPWpGaD
